Magnetic Resonance Spectroscopy in Alzheimer's Disease: Systematic Review and Meta-Analysis

Journal of Alzheimer's Disease

Volumn 46, Issue 4, 2015, Pages 1049-1070

  Wang, Hui ^a   Tan, Lan ^a,b,c   Wang, Hui Fu ^b   Liu, Ying ^a   Yin, Rui Hua ^b   Wang, Wen Ying ^b   Chang, Xiao Long ^b   Jiang, Teng ^d   Yu, Jin Tai ^b,c,d,e  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; choline; creatine; glutamate and glutamine; magnetic resonance spectroscopy; meta analysis; myo inositol; N acetyl aspartate

Indexed keywords

BIOLOGICAL MARKER; ASPARTIC ACID; CREATINE; N-ACETYLASPARTATE; PROTON;

ALZHEIMER DISEASE; BRAIN CORTEX; BRAIN METABOLISM; CONTROLLED CLINICAL TRIAL (TOPIC); DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HIPPOCAMPUS; HUMAN; MEDIAL TEMPORAL LOBE; MENTAL DETERIORATION; META ANALYSIS; METABOLITE; NEUTRON ACTIVATION ANALYSIS; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARASYMPATHETIC INNERVATION; PARIETAL LOBE; POSTERIOR CINGULATE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; BIBLIOGRAPHIC DATABASE; BRAIN; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ALZHEIMER DISEASE; ASPARTIC ACID; BRAIN; CREATINE; DATABASES, BIBLIOGRAPHIC; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PROTONS;

EID: 84937039514     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-143225     Document Type: Review

References (92)

1. De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV (2012) Alzheimer's disease. Subcell Biochem 65, 329-352.
2. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739, 198-210.
3. Lippa CF, Morris JC (2006) Alzheimer neuropathology in nondemented aging: Keeping mind over matter. Neurology 66, 1801-1802.
4. Cummings JL (2006) Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimers Dement 2, 263-271.
5. Zhu X, Cao L, Hu X, Dong Y, Wang H, Liu F, Sun Z (2015) Brain metabolism assessed via proton magnetic resonance spectroscopy in patients with amnestic or vascular mild cognitive impairment. Clin Neurol Neurosurg 130, 80-85.
6. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
7. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746.
8. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
9. Wagner JA (2009) Biomarkers: Principles, policies, and practice. Clin Pharmacol Ther 86, 3-7.
10. Montine T, Phelps C, Beach T, Bigio E, Cairns N, Dickson D, Duyckaerts C, Frosch M, Masliah E, Mirra S, Nelson P, Schneider J, Thal D, Trojanowski J, Vinters H, Hyman B (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 123, 1-11.
11. Kantarci K, Jack CR Jr., Xu YC, Campeau NG, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Kokmen E, Tangalos EG, Petersen RC (2000) Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 55, 210-217.
12. Fernandez A, Garcia-Segura JM, Ortiz T, Montoya J, Maestu F, Gil-Gregorio P, Campo P, Viano J (2005) Proton magnetic resonance spectroscopy and magnetoencephalographic estimation of delta dipole density: A combination of techniques that may contribute to the diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord 20, 169-177.
13. Kantarci K, Xu Y, Shiung MM, O'Brien PC, Cha RH, Smith GE, Ivnik RJ, Boeve BF, Edland SD, Kokmen E, Tangalos EG, Petersen RC, Jack CR Jr. (2002) Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 14, 198-207.
14. Martinez-Bisbal MC, Arana E, Marti-Bonmati L, Molla E, Celda B (2004) Cognitive impairment: Classification by 1H magnetic resonance spectroscopy. Eur J Neurol 11, 187-193.
15. Klunk WE, Panchalingam K, Moossy J, McClure RJ, Pettegrew JW (1992) N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: A preliminary proton nuclear magnetic resonance study. Neurology 42, 1578-1585.
16. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB (1996) Inhibition of N-acetylaspartate production: Implications for 1H MRS studies in vivo. Neuroreport 7, 1397-1400.
17. Tsai G, Coyle JT (1995) N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 46, 531-540.
18. Modrego PJ, Pina MA, Fayed N, Diaz M (2006) Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: A nonrandomised controlled trial with magnetic resonance spectroscopy. CNS Drugs 20, 867-877.
19. Klein J (2000) Membrane breakdown in acute and chronic neurodegeneration: Focus on choline-containing phospholipids. J Neural Transm 107, 1027-1063.
20. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O'Brien PC, Weigand SD, Edland SD, Smith GE, Ivnik RJ, Ferman TJ, Tangalos EG, Jack CR Jr (2004) 1H MR spectroscopy in common dementias. Neurology 63, 1393-1398.
21. Meyerhoff DJ, MacKay S, Constans JM, Norman D, Van Dyke C, Fein G, Weiner MW (1994) Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Ann Neurol 36, 40-47.
22. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S (2003) Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 160, 2003-2011.
23. Pouwels PJ, Frahm J (1998) Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med 39, 53-60.
24. Kreis R, Ernst T, Ross BD (1993) Development of the human brain: In vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med 30, 424-437.
25. Li BS, Wang H, Gonen O (2003) Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magn Reson Imaging 21, 923-928.
26. Fisher SK, Novak JE, Agranoff BW (2002) Inositol and higher inositol phosphates in neural tissues: Homeostasis, metabolism and functional significance. J Neurochem 82, 736-754.
27. Antuono PG, Jones JL, Wang Y, Li SJ (2001) Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T. Neurology 56, 737-742.
28. Hattori N, Abe K, Sakoda S, Sawada T (2002) Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport 13, 183-186.
29. Ding B, Chen KM, Ling HW, Zhang H, Chai WM, Li X, Wang T (2008) Diffusion tensor imaging correlates with proton magnetic resonance spectroscopy in posterior cingulate region of patients with Alzheimer's disease. Dement Geriatr Cogn Disord 25, 218-225.
30. Jessen F, Block W, Traber F, Keller E, Flacke S, Papassotiropoulos A, Lamerichs R, Heun R, Schild HH (2000) Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 55, 684-688.
31. Schuff N, Amend DL, Meyerhoff DJ, Tanabe JL, Norman D, Fein G, Weiner MW (1998) Alzheimer disease: Quantitative H-1 MR spectroscopic imaging of frontoparietal brain. Radiology 207, 91-102.
32. Ackl N, Ising M, Schreiber YA, Atiya M, Sonntag A, Auer DP (2005) Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neurosci Lett 384, 23-28.
33. Doraiswamy PM, Charles HC, Krishnan KR (1998) Prediction of cognitive decline in early Alzheimer's disease. Lancet 352, 1678.
34. Kantarci K, Smith GE, Ivnik RJ, Petersen RC, Boeve BF, Knopman DS, Tangalos EG, Jack CR Jr. (2002) 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc 8, 934-942.
35. Angelie E, Bonmartin A, Boudraa A, Gonnaud PM, Mallet JJ, Sappey-Marinier D (2001) Regional differences and metabolic changes in normal aging of the human brain: Proton MR spectroscopic imaging study. AJNR Am J Neuroradiol 22, 119-127.
36. Gordon ML, Kingsley PB, Goldberg TE, Koppel J, Christen E, Keehlisen L, Kohn N, Davies P (2012) An open-label exploratory study with memantine: Correlation between proton magnetic resonance spectroscopy and cognition in patients with mild to moderate Alzheimer's disease. Dement Geriatr Cogn Dis Extra 2, 312-320.
37. Modrego PJ, Fayed N, Errea JM, Rios C, Pina MA, Sarasa M (2010) Memantine versus donepezil in mild to moderate Alzheimer's disease: A randomized trial with magnetic resonance spectroscopy. Eur J Neurol 17, 405-412.
38. van Wageningen H, Jorgensen HA, Specht K, Hugdahl K (2010) A 1H-MR spectroscopy study of changes in glutamate and glutamine (Glx) concentrations in frontal spectra after administration of memantine. Cereb Cortex 20, 798-803.
39. Chantal S, Labelle M, Bouchard RW, Braun CM, Boulanger Y (2002) Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease. Arch Neurol 59, 955-962.
40. Senn SJ (2009) Overstating the evidence: Double counting in meta-analysis and related problems. BMC Med Res Methodol 9, 10.
41. Mandal PK, Pettegrew JW, McKeag DW, Mandal R (2006) Alzheimer's disease: Halothane induces Abeta peptide to oligomeric form-solution NMR studies. Neurochem Res 31, 883-890.
42. Penner J, Rupsingh R, Smith M, Wells JL, Borrie MJ, Bartha R (2010) Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 34, 104-110.
43. Shinno H, Inagaki T, Miyaoka T, Okazaki S, Kawamukai T, Utani E, Inami Y, Horiguchi J (2007) A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease. J Neurol Sci 260, 132-138.
44. Borenstein M, Hedges LV, Higgins JPT, Rothstein H (2009) Computing Effect Sizes for Meta-analysis, John Wiley & Sons, UK.
45. Cohen J (1992) A power primer. Psychol Bull 112, 155-159.
46. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21, 1539-1558.
47. Fayed N, Modrego PJ, Rojas-Salinas G, Aguilar K (2011) Brain glutamate levels are decreased in Alzheimer's disease: A magnetic resonance spectroscopy study. Am J Alzheimers Dis Other Demen 26, 450-456.
48. Griffith HR, den Hollander JA, Stewart CC, Evanochko WT, Buchthal SD, Harrell LE, Zamrini EY, Brockington JC, Marson DC (2007) Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease. NMR Biomed 20, 709-716.
49. Kantarci K, Weigand SD, Petersen RC, Boeve BF, Knopman DS, Gunter J, Reyes D, Shiung M, O'Brien PC, Smith GE, Ivnik RJ, Tangalos EG, Jack CR Jr. (2007) Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 28, 1330-1339.
50. Lim TS, Hong YH, Choi JY, Kim HS, Moon SY (2012) Functional investigation of bilateral posterior cingulate gyri using multivoxel MR spectroscopy. Eur Neurol 67, 279-286.
51. Lim TS, Hong YH, Lee HY, Choi JY, Kim HS, Moon SY (2012) Metabolite investigation in both anterior and posterior cingulate gyri in Alzheimer's disease spectrum using 3-tesla MR spectroscopy. Dement Geriatr Cogn Disord 33, 149-155.
52. Shiino A, Watanabe T, Shirakashi Y, Kotani E, Yoshimura M, Morikawa S, Inubushi T, Akiguchi I (2012) The profile of hippocampal metabolites differs between Alzheimer's disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy. J Cereb Blood Flow Metab 32, 805-815.
53. Silveira de Souza A, de Oliveira-Souza R, Moll J, Tovar-Moll F, Andreiuolo PA, Bottino CM (2011) Contribution of 1H spectroscopy to a brief cognitive-functional test battery for the diagnosis of mild Alzheimer's disease. Dement Geriatr Cogn Disord 32, 351-361.
54. Wang T, Xiao S, Li X, Ding B, Ling H, Chen K, Fang Y (2012) Using proton magnetic resonance spectroscopy to identify mild cognitive impairment. Int Psychogeriatr 24, 19-27.
55. Wang Z, Zhao C, Yu L, Zhou W, Li K (2009) Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease. Acta Radiol 50, 312-319.
56. Watanabe T, Shiino A, Akiguchi I (2010) Absolute quantification in proton magnetic resonance spectroscopy is useful to differentiate amnesic mild cognitive impairment from Alzheimer's disease and healthy aging. Dement Geriatr Cogn Disord 30, 71-77.
57. Watanabe T, Shiino A, Akiguchi I (2012) Hippocampal metabolites and memory performances in patients with amnestic mild cognitive impairment and Alzheimer's disease. Neurobiol Learn Mem 97, 289-293.
58. Zimny A, Szewczyk P, Trypka E, Wojtynska R, Noga L, Leszek J, Sasiadek M (2011) Multimodal imaging in diagnosis of Alzheimer's disease and amnestic mild cognitive impairment: Value of magnetic resonance spectroscopy, perfusion, and diffusion tensor imaging of the posterior cingulate region. J Alzheimers Dis 27, 591-601.
59. Graff-Radford J, Boeve BF, Murray ME, Ferman TJ, Tosakulwong N, Lesnick TG, Maroney-Smith M, Senjem ML, Gunter J, Smith GE, Knopman DS, Jack CR Jr., Dickson DW, Petersen RC, Kantarci K (2014) Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiol Aging 35, 1483-1490.
60. Fayed N, Andres E, Viguera L, Modrego PJ, Garcia-Campayo J (2014) Higher glutamate + glutamine and reduction of N-acetylaspartate in posterior cingulate according to age range in patients with cognitive impairment and/or pain. Acad Radiol 21, 1211-1217.
61. Frederick BD, Lyoo IK, Satlin A, Ahn KH, Kim MJ, Yurgelun-Todd DA, Cohen BM, Renshaw PF (2004) In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 28, 1313-1322.
62. Foy CM, Daly EM, Glover A, O'Gorman R, Simmons A, Murphy DG, Lovestone S (2011) Hippocampal proton MR spectroscopy in early Alzheimer's disease and mild cognitive impairment. Brain Topogr 24, 316-322.
63. Block W, Jessen F, Traber F, Flacke S, Manka C, Lamerichs R, Keller E, Heun R, Schild H (2002) Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease. Arch Neurol 59, 828-834.
64. Chao LL, Schuff N, Kramer JH, Du AT, Capizzano AA, O'Neill J, Wolkowitz OM, Jagust WJ, Chui HC, Miller BL, Yaffe K, Weiner MW (2005) Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients. Neurology 64, 282-289.
65. Schuff N, Capizzano AA, Du AT, Amend DL, O'Neill J, Norman D, Kramer J, Jagust W, Miller B, Wolkowitz OM, Yaffe K, Weiner MW (2002) Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 58, 928-935.
66. Azevedo D, Tatsch M, Hototian SR, Bazzarella MC, Castro CC, Bottino CM (2008) Proton spectroscopy in Alzheimer's disease and cognitive impairment no dementia: A community-based study. Dement Geriatr Cogn Disord 25, 491-500.
67. Herminghaus S, Frolich L, Gorriz C, Pilatus U, Dierks T, Wittsack HJ, Lanfermann H, Maurer K, Zanella FE (2003) Brain metabolism in Alzheimer disease and vascular dementia assessed by in vivo proton magnetic resonance spectroscopy. Psychiatry Res 123, 183-190.
68. Siger M, Schuff N, Zhu X, Miller BL, Weiner MW (2009) Regional myo-inositol concentration in mild cognitive impairment Using 1H magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord 23, 57-62.
69. Stoppe G, Bruhn H, Pouwels PJ, Hanicke W, Frahm J (2000) Alzheimer disease: Absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy. Alzheimer Dis Assoc Disord 14, 112-119.
70. Zhu X, Schuff N, Kornak J, Soher B, Yaffe K, Kramer JH, Ezekiel F, Miller BL, Jagust WJ, Weiner MW (2006) Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord 20, 77-85.
71. Parnetti L, Tarducci R, Presciutti O, Lowenthal DT, Pippi M, Palumbo B, Gobbi G, Pelliccioli GP, Senin U (1997) Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech Ageing Dev 97, 9-14.
72. Catani M, Cherubini A, Howard R, Tarducci R, Pelliccioli GP, Piccirilli M, Gobbi G, Senin U, Mecocci P (2001) (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 12, 2315-2317.
73. Mayeux R, Sano M (1999) Treatment of Alzheimer's disease. N Engl J Med 341, 1670-1679.
74. McLendon BM, Chen GG, Doraiswamy PM (2000) Current and future treatments for cognitive deficits in dementia. Curr Psychiatry Rep 2, 20-23.
75. Ashford JW, Adamson M, Beale T, La D, Hernandez B, Noda A, Rosen A, O'Hara R, Fairchild JK, Spielman D, Yesavage JA (2011) MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia. J Alzheimers Dis 26(Suppl 3), 331-336.
76. Frederick B, Satlin A, Wald LL, Hennen J, Bodick N, Renshaw PF (2002) Brain proton magnetic resonance spectroscopy in Alzheimer disease: Changes after treatment with xanomeline. Am J Geriatr Psychiatry 10, 81-88.
77. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364.
78. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM (2007) N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology. Prog Neurobiol 81, 89-131.
79. De Stefano N, Matthews PM, Arnold DL (1995) Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 34, 721-727.
80. Signoretti S, Marmarou A, Tavazzi B, Lazzarino G, Beaumont A, Vagnozzi R (2001) N-Acetylaspartate reduction as a measure of injury severity and mitochondrial dysfunction following diffuse traumatic brain injury. J Neurotrauma 18, 977-991.
81. Kantarci K, Knopman DS, Dickson DW, Parisi JE, Whitwell JL, Weigand SD, Josephs KA, Boeve BF, Petersen RC, Jack CR Jr. (2008) Alzheimer disease: Postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 248, 210-220.
82. Huang W, Alexander GE, Chang L, Shetty HU, Krasuski JS, Rapoport SI, Schapiro MB (2001) Brain metabolite concentration and dementia severity in Alzheimer's disease: A (1)H MRS study. Neurology 57, 626-632.
83. Watanabe T, Shiino A, Akiguchi I (2008) Absolute quantification in proton magnetic resonance spectroscopy is superior to relative ratio to discriminate Alzheimer's disease from Binswanger's disease. Dement Geriatr Cogn Disord 26, 89-100.
84. Kantarci K (2007) 1H magnetic resonance spectroscopy in dementia. Br J Radiol 80 Spec No 2, S146-S152.
85. Alger JR (2010) Quantitative proton magnetic resonance spectroscopy and spectroscopic imaging of the brain: A didactic review. Top Magn Reson Imaging 21, 115-128.
86. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292.
87. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
88. Catani M, Mecocci P, Tarducci R, Howard R, Pelliccioli GP, Mariani E, Metastasio A, Benedetti C, Senin U, Cherubini A (2002) Proton magnetic resonance spectroscopy reveals similar white matter biochemical changes in patients with chronic hypertension and early Alzheimer's disease. J Am Geriatr Soc 50, 1707-1710.
89. Ernst T, Chang L, Melchor R, Mehringer CM (1997) Frontotemporal dementia and early Alzheimer disease: Differentiation with frontal lobe H-1 MR spectroscopy. Radiology 203, 829-836.
90. Jessen F, Gur O, Block W, Ende G, Frolich L, Hammen T, Wiltfang J, Kucinski T, Jahn H, Heun R, Maier W, Kolsch H, Kornhuber J, Traber F (2009) A multicenter (1)H-MRS study of the medial temporal lobe in AD and MCI. Neurology 72, 1735-1740.
91. Jessen F, Traeber F, Freymann N, Maier W, Schild HH, Heun R, Block W (2005) A comparative study of the different N-acetylaspartate measures of the medial temporal lobe in Alzheimer's disease. Dement Geriatr Cogn Disord 20, 178-183.
92. MacKay S, Meyerhoff DJ, Constans JM, Norman D, Fein G, Weiner MW (1996) Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging. Arch Neurol 53, 167-174.